Loss of Liver Kinase B1 (LKB1) in Beta Cells Enhances Glucose-stimulated Insulin Secretion Despite Profound Mitochondrial Defects
Overview
Authors
Affiliations
The tumor suppressor liver kinase B1 (LKB1) is an important regulator of pancreatic β cell biology. LKB1-dependent phosphorylation of distinct AMPK (adenosine monophosphate-activated protein kinase) family members determines proper β cell polarity and restricts β cell size, total β cell mass, and glucose-stimulated insulin secretion (GSIS). However, the full spectrum of LKB1 effects and the mechanisms involved in the secretory phenotype remain incompletely understood. We report here that in the absence of LKB1 in β cells, GSIS is dramatically and persistently improved. The enhancement is seen both in vivo and in vitro and cannot be explained by altered cell polarity, increased β cell number, or increased insulin content. Increased secretion does require membrane depolarization and calcium influx but appears to rely mostly on a distal step in the secretion pathway. Surprisingly, enhanced GSIS is seen despite profound defects in mitochondrial structure and function in LKB1-deficient β cells, expected to greatly diminish insulin secretion via the classic triggering pathway. Thus LKB1 is essential for mitochondrial homeostasis in β cells and in parallel is a powerful negative regulator of insulin secretion. This study shows that β cells can be manipulated to enhance GSIS to supra-normal levels even in the face of defective mitochondria and without deterioration over months.
Liver kinase B1 (LKB1) regulates the epigenetic landscape of mouse pancreatic beta cells.
Haberman N, Cheung R, Pizza G, Cvetesic N, Nagy D, Maude H FASEB J. 2024; 38(16):e23885.
PMID: 39139039 PMC: 11378476. DOI: 10.1096/fj.202401078R.
Guzel S, Yalcin A, Gurpinar Y, Guler S Turk J Med Sci. 2024; 53(6):1565-1573.
PMID: 38813509 PMC: 10760535. DOI: 10.55730/1300-0144.5725.
Mitochondrial bioenergetics, metabolism, and beyond in pancreatic β-cells and diabetes.
Rivera Nieves A, Wauford B, Fu A Front Mol Biosci. 2024; 11:1354199.
PMID: 38404962 PMC: 10884328. DOI: 10.3389/fmolb.2024.1354199.
Mark Evans A Adv Exp Med Biol. 2023; 1427:163-173.
PMID: 37322347 DOI: 10.1007/978-3-031-32371-3_18.
Signaling pathways and intervention for therapy of type 2 diabetes mellitus.
Cao R, Tian H, Zhang Y, Liu G, Xu H, Rao G MedComm (2020). 2023; 4(3):e283.
PMID: 37303813 PMC: 10248034. DOI: 10.1002/mco2.283.